Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma

[1]  R. Gorlick,et al.  Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma , 2014, Cancer.

[2]  B. Meibohm,et al.  Population Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.

[3]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[4]  Jos H. Beijnen,et al.  Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.

[5]  K. Matthay,et al.  Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  W Wang,et al.  Monoclonal Antibody Pharmacokinetics and Pharmacodynamics , 2008, Clinical pharmacology and therapeutics.

[7]  S. Hettmer,et al.  Low complex ganglioside expression characterizes human neuroblastoma cell lines. , 2005, Cancer letters.

[8]  Renate Kunert,et al.  Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. , 2005, Molecular immunology.

[9]  M. Uttenreuther-Fischer,et al.  Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients , 1995, Cancer Immunology, Immunotherapy.

[10]  Huub Schellekens,et al.  Immunogenicity of therapeutic proteins: clinical implications and future prospects. , 2002, Clinical therapeutics.

[11]  N. Cheung,et al.  GD2 synthase , 2001, Cancer.

[12]  K. Matthay,et al.  Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Uttenreuther-Fischer,et al.  Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Bechhofer,et al.  Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  T. Voepel-Lewis,et al.  The FLACC: a behavioral scale for scoring postoperative pain in young children. , 1997, Pediatric nursing.

[16]  M. Ross,et al.  Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[17]  M. Schrappe,et al.  A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. , 1995, European journal of cancer.

[18]  J. Månsson,et al.  Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. , 1994, Biochimica et biophysica acta.

[19]  R K Jain,et al.  Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. , 1994, Cancer research.

[20]  W. Grizzle,et al.  Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. , 1992, Human antibodies and hybridomas.

[21]  J. Rapola,et al.  Cell-surface ganglioside GD2 in the immunohistochemical detection and differential diagnosis of neuroblastoma. , 1991, American journal of clinical pathology.

[22]  N. Berger,et al.  Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Seeger,et al.  Expression of GD2 ganglioside by untreated primary human neuroblastomas. , 1986, Cancer research.

[24]  D. Cheresh,et al.  Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. , 1984, Proceedings of the National Academy of Sciences of the United States of America.